ALDH1A1 and pancreatic neoplasm: Related to this study, our recent study has demonstrated that dasatinib enhances gemcitabine-induced decreased ALDH1A1 expression and increased cell death of MIA PaCa-2 pancreatic cancer cells with acquired resistance to gemcitabine [17].